Abstract Background Sub-Saharan Africa carries the highest HIV burden globally. It is
important to understand how interventions cost-effectively fit within guidelines and …

In this guideline, WHO recommends that long-acting injectable cabotegravir (CAB-LA) may
be offered as an additional HIV prevention option for people at substantial risk of HIV …

Introduction Several low‐and middle‐income countries (LMICs) are preparing to introduce
long‐acting pre‐exposure prophylaxis (LAP). Amid multiple pre‐exposure prophylaxis …

Background Long-acting injectable cabotegravir, a drug taken every 2 months, has been
shown to be more effective at preventing HIV infection than daily oral tenofovir disoproxil …

Risk of HIV infection is high in Chinese MSM, with an annual HIV incidence ranging from
3.41 to 13.7/100 person-years. Tenofovir-based PrEP is effective in preventing HIV …

Introduction The proven effectiveness of injectable cabotegravir (CAB‐LA) is higher than that
of any other HIV prevention intervention ever trialled or implemented, surpassing medical …

Background Although effective, some oral pre-exposure prophylaxis (PrEP) users face
barriers to adherence using daily pills, which could be reduced by long-acting formulations …

Abstract Introduction In 2014, the Government of Thailand recommended pre‐exposure
prophylaxis (PrEP) as an additional HIV prevention programme within Thailand's National …

Methods: Epidemiological and costing models estimated the one-year costs and outcomes
associated with PrEP use in 3 scenarios. PrEP uptake was estimated for younger (aged 18 …

Introduction: Although pre-exposure prophylaxis (PrEP.) is an efficacious HIV prevention
strategy, its preventive benefit has not been shown among young women in sub-Saharan …